is more common, and has a worse outcome, in patients with inflammatory bowel disease [IBD] than in those without. We have now reassessed the incidence and outcome of CDI in in-patients with and without IBD, and the outcomes of admissions for IBD patients with and without CDI. Methods: In-patients who had stool samples submitted for C. difficile testing [2007][2008][2009][2010][2011][2012][2013] ). IBD patients were diagnosed with CDI earlier in their admission than non-IBD patients . No differences in mortality were found. Conclusions: The incidence of CDI complicating IBD has fallen since 2007. CDI is no longer associated with worse short-term outcomes in patients with IBD than in those without. Patients with CDI and IBD have similar outcomes to those with IBD alone.
Introduction
The Gram-positive anaerobe Clostridium difficile is the major cause of antibiotic-associated diarrhoea in hospitalized patients. Patients with inflammatory bowel disease [IBD] have previously been reported to have a higher incidence of C. difficile infection [CDI] than non-IBD patients, 1, 2, 3, 4, 5 as well as poorer outcomes with longer lengths of stay. 6 IBD patients with CDI have also been reported to have increased mortality 4, 7 and higher colectomy rates 4, 8 than IBD patients without CDI. Since 2007 in the UK, overall CDI rates have fallen 9 and outcomes have improved. 10 It is not known if these trends are being mirrored in the IBD population. In this study, we have performed two separate matching procedures to undertake a comparative analysis to see if incidence and outcome of CDI in IBD in-patients have changed. We matched and compared, firstly, IBD inpatients with concurrent CDI to non-IBD in-patients with CDI, and, secondly, IBD in-patients with CDI to IBD in-patients without CDI.
Materials and Methods

Clinical setting
This study was undertaken at a tertiary referral centre [Barts Health NHS Trust, London, UK].
Studies performed
The recent incidence and outcome of CDI in in-patients with and without IBD was determined and compared. This was performed by comparing the following groups: in-patients with IBD and CDI vs non-IBD in-patients with CDI, and in-patients with IBD and CDI vs IBD in-patients without CDI.
The Barts Health microbiology database [WinPath version 5.27.17, CliniSys Solutions Ltd, Chertsey, UK] was retrospectively searched for all in-patient stool samples tested for C. difficile over a 6-year period [ending December 2013] . Samples testing positive for CDI by toxin B enzyme-linked immunosorbent assay [Meridian Bioscience, London, UK for samples before April 2012 and ToxQuik Check, Alere Limited, Stockport, UK for samples after April 2012] were selected. It has been our centre's policy to test all diarrhoeal patients [with or without IBD] for CDI and it was assumed that the vast majority of in-patients with diarrhoea had stool submitted for C. difficile testing. Therefore, incidence of CDI was calculated using the number of stool samples submitted for testing as the denominator.
For each sample, electronic patient records were searched to determine IBD status, admission details, and pre-admission and outcome data. For CDI patients who had IBD, disease diagnosis and distribution was also determined. CDI-negative IBD patients were identified by cross-referencing the IBD patient database with the patients who tested negative for CDI.
The UK National IBD Audit is run by the Royal College of Physicians with the aim of improving the safety and quality of care for IBD patients in the UK. Site-specific admission numbers from adult audit rounds 2-4 [2007/08, 2008/09 and 2012/13, respectively] 11 were used as denominators to calculate the percentage of patients admitted with IBD who developed CDI. It was not possible to determine the number of IBD admissions outside the audit time frames.
Non-IBD patients with CDI were expected to be older than IBD patients with CDI 12 and to have a worse outcome on these grounds alone. To allow direct comparison of the outcome of CDI in IBD and non-IBD in-patients we therefore used age-based matching [Matching method 1 below]; we also used age matching to compare outcomes in IBD in-patients with and without CDI [Matching method 2 below]. 
Ethics
The NHS National Research Authority's and Medical Research Council's joint 'Is my study research?' tool 13 was used to determine if formal ethical approval was required. The study was not considered to be research and therefore formal ethical approval was not sought. Our view was that the findings would not necessarily be generalizable worldwide. They are UK-based and derive from a specialist IBD service in a tertiary referral centre in a deprived inner city area. Nevertheless, the findings provide information which might prove to be of interest to centres elsewhere.
Results
Data extraction
In total, 21 035 in-patient stool samples were sent for C. difficile testing in the study period [2007] [2008] [2009] [2010] [2011] [2012] [2013] . Of those, 1079 [4%] were positive for CDI of which 49 [5%] were from IBD patients. In total, 20 226 [96%] samples were negative for CDI; 363 [2%] of these were identified as coming from patients with IBD by cross-referencing against our IBD patient database [consort diagrams: Figure 1 ]. Local results from the adult National IBD Audit rounds 2-4 showed that 104, 154 and 237 IBD patients were admitted during 2007/08, 2008/09 and 2012/13, respectively; our C. difficile testing rates for adults over these years were 93%, 89% [UC]/70% [Crohn's] and 70%, respectively. We were unable to ascertain accurately the proportion of stools from non-IBD diarrhoeal patients in the hospital over this period that were tested for C. difficile, not least because in many instances diarrhoea was a transient feature of patients' admissions not coded on their discharge summaries.
Incidence of CDI in in-patients with IBD
The number of all in-patients diagnosed annually with CDI declined over the study period from 369 in 2007/08 to 62 in 2012/13. Using local admission data from the UK National IBD Audit rounds to provide the denominator, in 2007/08 8.7% of all IBD in-patients were diagnosed with CDI; this figure fell to 4.5% for 2008/09 and 0.4% for 2012/13 (p < 0.0001).
IBD characteristics in in-patients with CDI
Of all the IBD patients with CDI [n = 49], 71% [n = 35] had UC. Of the 14 patients with Crohn's and CDI, 86% [n = 12] had colonic involvement.
Outcome
As shown in Table 1 and Figure 2 [A-C], IBD in-patients with CDI had shorter lengths of stay, and after being diagnosed with CDI were discharged sooner than non-IBD patients with CDI. Patients with IBD were also diagnosed with CDI earlier in their admission than non-IBD patients. None of the other clinical information collected showed significant differences between the two groups. The antibiotic exposure data sets were incomplete.
Two IBD patients died during the admission in which they were diagnosed with CDI. One died of bronchopneumonia secondary to chronic obstructive pulmonary disease [age 78] and the other of multiorgan failure secondary to neutropenic sepsis following chemotherapy for chronic myeloid leukaemia [age 62]. In both cases, the patients' IBD was inactive. It was not possible to ascertain whether the acquisition of CDI in these two patients was related to them having pre-existing IBD.
As shown in Table 2 and Figure 2 [D], there was no difference in the length of stay in the IBD patients with and without CDI. None of the other clinical information collected showed significant differences between the two groups of patients with IBD. The antibiotic exposure datasets were incomplete.
Discussion
We have shown that the incidence of CDI at our centre in in-patients with IBD has fallen from 8.7% in 2007/08 to 0.4% in 2012/13. UK data on the incidence of CDI in hospitalized patients with IBD decades, including the introduction of anti-tumour necrosis factor α agents, has improved mucosal function and thereby reduced patients' chances of colonization by C. difficile [and subsequent damage to their mucosa by C. difficile toxin]. In this context too, our data were collected in a specialist tertiary IBD referral centre, where a major focus in recent years has been to optimize maintenance of remission. The fall in incidence of CDI in our IBD patients was not due to reduced testing of stools for C. difficile, as evidenced by the steady testing rates recorded over the study period for the UK National IBD Audit. In our study, as in others' [reviewed by Goodhand et al. 12 ], CDI affected patients with UC more commonly than those with Crohn's. Furthermore in patients with Crohn's, CDI was more common when there was colonic involvement, a finding that may reflect the preferential localization of C. difficile to already abnormal colonic mucosa.
IBD patients with CDI have been previously reported to have greater in-patient mortality when compared to non-IBD patients with CDI, 4,7 as well as when compared to IBD patients without CDI. 6 Our data do not confirm these observations. IBD patients with CDI tend to be younger than non-IBD CDI patients 12 but, when accounted for this potential difference by matching for age, we found a trend to lower mortality in IBD than in non-IBD in-patients with CDI [ Table 1 ].
In contrast to a previously published series, 6 IBD patients with CDI in this study had shorter lengths of stay than non-IBD patients. The shorter lengths of stay in the IBD group can be explained partly by the fact that IBD patients are usually diagnosed with CDI earlier in their admission than non-IBD patients and therefore receive CDI treatment sooner. 1 The difference in time to diagnosis of CDI between IBD and non-IBD patients is probably because the former are more likely to be admitted to hospital with diarrhoea than the non-IBD population, who tend to develop diarrhoea during the course of their admission. It is also likely that there is now a higher index of clinical suspicion for CDI when IBD patients present with diarrhoea than when non-IBD patients do so. As a result of this, as well as of recent UK and European guidelines, 15, 16 IBD patients with CDI may now be identified and treated earlier than they were previously, 6 a factor likely to contribute to improved clinical outcome.
When IBD patients with CDI were compared to IBD patients without CDI, we found no difference in length of stay. This is in contrast to older published UK data showing that CDI in IBD increases length of stay by almost 1 month when compared to IBD patients without CDI. 6 There are several possible reasons for these discrepant findings. First, in Jen et al.'s study, 6 the data reported covered the years 2002-2008, which was before CDI testing in most centres had become routine in all patients with diarrhoea. Ten or more years ago, testing for CDI in IBD was restricted largely to those patients who were not responding to usual flare management: the increased awareness of CDI now, and the more modern guideline-directed practice of testing for C. difficile in all diarrhoeal IBD in-patients, 15, 16 may be identifying patients with less severe CDI, who respond more quickly to treatment and who were missed in the past. Secondly, patients in that earlier period whose symptoms were in fact due to CDI not detected until later in their illness may have been given corticosteroids inappropriately, with a subsequent worsening of their disease course. 17 Similar arguments are likely to explain the differences in our outcome data from those published from the USA, 4, 7, 8 where, in addition, the threshold for surgery might be different from that in the UK. Lastly, the differences between the methods of collection of the relevant data may contribute to the discrepant findings.
There were no C. difficile-related colectomies on index admission or in the follow-up period in either our IBD or our non-IBD groups. Conversely, a report covering three 1-year periods [1998, 2004 and 2007] showed consecutively increasing colectomy rates for IBD patients who also develop CDI. 4 Other studies that have looked at colectomy rates in UC patients with CDI have reported rates of 36% 18 and 45% 8 over the subsequent year. An explanation for this discrepant finding is that the datasets from the published studies are not up to date; 1998-2007, 
Study strengths and limitations
Our matched studies have several strengths. Because patients with CDI are generally older than patients with IBD, 12 matching for age restricted age-related bias. IBD type and location has been associated with differing risks of CDI 12 and matching for this variable further reduced bias. Matching to sample date also controlled for temporal changes in the overall incidence of CDI. 9 We used patient-level data, which circumvented inaccuracies sometimes associated with studies using databases, especially if the databases used were not designed to answer a specific research question. 19 Matching was performed blinded, which minimized selection bias.
Conversely, this work has a number of limitations. As this was a single centre study, its findings may not be representative of areas or countries where overall CDI rates remain high. 20 We also acknowledge that the sample size was relatively small and consequently that some of our conclusions might be subject to a type II statistical error. The retrospective nature of the study could also be considered a limitation, but with the low numbers of CDI cases in patients with IBD that were found, a fully powered prospective study would take several years to complete. Lastly, the incompleteness of our data about antibiotic usage precludes any comment on possible differences between the groups in this respect.
Conclusions
Detailed retrospective matched studies using patient-level data investigating the incidence and outcome of CDI in the IBD population have shown that the incidence of CDI complicating IBD in the UK is lower than it used to be, and that CDI is no longer associated with worse outcomes than in the non-IBD population. The extent to which these changes have also occurred in other countries, and reflect improved care of IBD patients rather than simply an overall reduction in the incidence of CDI in hospitals as a result of improved infection control,
is not yet clear. It remains important, despite these uncertainties, to test for CDI in diarrhoeal patients whether or not they have IBD.
Funding
None.
Conflict of Interest
None. 
